Are STK11 Polymorphisms a Predictor of the Response to Metformin in Polycystic Ovarian Syndrome?

This study investigated the relationship between Serine threonine kinase 11 (STK11) gene polymorphisms and the response to metformin in 57 women with polycystic ovary syndrome (PCOS). Participants were followed for 6 menstrual cycles while on metformin therapy (850 mg, twice daily). The study found significant improvements in menstrual frequency, blood loss, acne, ultrasound findings, and a decrease in BMI, acne, and hirsutism after metformin therapy, with a significant decrease in fasting insulin but not in fasting blood sugar. However, there were no significant changes in alopecia. The frequencies of the genotypes of intron 1 of the STK11 gene were 26% CC, 44% CG, and 30% GG, and of intron 6 were 52% CC, 37% CT, and 11% TT genotype. While there was a significant difference in relation to alopecia in the Intron 1 subgroups, and in relation to hirsutism score in the Intron 6 subgroups, the study concluded that STK11 gene polymorphisms were not predictive of the overall response to metformin therapy, although they may have some effect on alopecia and hirsutism.